Trial Profile
A Double-blind, Active-controlled, Randomized Study Comparing Mirtazapine Combined With Paroxetine or Paroxetine Monotherapy in Patients With Major Depressive Patients Without Early Improvement in the First 2 Weeks
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Mirtazapine (Primary) ; Paroxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 07 Feb 2022 Results of post-hoc analysis of data originated from this 2-week open-label phase of a multicenter clinical trial published in the Journal of Affective Disorders
- 28 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov
- 01 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.